Endogenous Small Molecule Proximity Methylator For Targeted Lysosomal Degradation Of Disease-Causing Proteins

Brief Description

A novel chemically inducible platform that directs arginine methylation to target proteins, enabling their selective lysosomal degradation.

Full Description

MrTAC is a protein degradation platform that uses PRMT-mediated arginine methylation to drive lysosomal degradation of disease-relevant proteins. Unlike proteasome-based degraders, it enables elimination of previously inaccessible targets through a fully endogenous, proximity-induced mechanism without genetic manipulation.

Suggested uses

• Therapeutic development for disease-associated proteins resistant to existing degraders. 
• Drug discovery and research tools for tissue-specific, endogenous protein degradation and proteostasis studies. 
• Platform for next-generation therapeutics, including cancer treatments and proximity-induced small molecules

Advantages

• Introduces an endogenous, PRMT-driven lysosomal degradation mechanism distinct from proteasome-based approaches and without genetic modification. 
• Expands the degradable target space, enabling removal of disease-relevant and previously intractable proteins across diverse cellular contexts. 
• Provides a modular, tissue-specific platform using multiple PRMTs to study methylation-dependent lysosomal degrons and proteostasis.

Patent Status

Patent Pending